MDCXW
MaterialsMedicus Pharma Ltd warrant
$0.50-0.03 (-6.10%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MDCXW Today?
No stock-specific AI insight has been generated for MDCXW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$485,152.94
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding971K
MDCXW News
20 articles- EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer StudyYahoo Finance·May 7, 2026
- Medicus Pharma reports strong Phase 2 dose response in skin cancer studyYahoo Finance·May 6, 2026
- Medicus Pharma highlights positive dose-response in updated skin cancer trial resultsProactive Investors·May 6, 2026
- Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-ResponseYahoo Finance·May 6, 2026
- Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndromeProactive Investors·Apr 27, 2026
- Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol HillYahoo Finance·Apr 27, 2026
- New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO GlobalYahoo Finance·Apr 25, 2026
- Medicus Pharma advances Skinject in rare disease – ICYMIProactive Investors·Apr 24, 2026
- Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indicationYahoo Finance·Apr 20, 2026
- New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)Yahoo Finance·Apr 18, 2026
- Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorderProactive Investors·Apr 17, 2026
- Dow rockets higher as Strait of Hormuz stays open, talks eyedProactive Investors·Apr 17, 2026
- Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin SyndromeYahoo Finance·Apr 17, 2026
- Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone SuppressionYahoo Finance·Apr 15, 2026
- Medicus Pharma to present new Teverelix data at upcoming endocrinology meetingProactive Investors·Apr 15, 2026
- New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)Yahoo Finance·Apr 11, 2026
- Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMIProactive Investors·Apr 10, 2026
- New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) PlatformsYahoo Finance·Apr 7, 2026
- Nasdaq leads Wall Street higher in the face of Iran tensions and oil volatilityProactive Investors·Apr 6, 2026
- Medicus Pharma submits optimized Phase 2 study design for TeverelixYahoo Finance·Apr 6, 2026
All 20 articles loaded
Price Data
Open$0.31
Previous Close$0.53
Day High$0.46
Day Low$0.31
52 Week High—
52 Week Low—
Fundamentals
Market Cap$485,152.94
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding971K
About Medicus Pharma Ltd warrant
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—